Critical Analysis of the Updated Guidelines for Management of Gallbladder Polyps Hassan AzizD. Brock HewittTimothy M. Pawlik ASO Perspectives 13 April 2022 Pages: 3363 - 3365
Repeat CRS/HIPEC: It Comes Down to Tumor Biology and Ability to Achieve a Complete CRS Konstantinos I. Votanopoulos Peritoneal Surface Malignancy 18 February 2022 Pages: 3366 - 3368
Deciphering the Etiology of Weight Loss Following Pancreatectomy Zhi Ven FongMotaz Qadan Pancreatic Tumors 04 February 2022 Pages: 3369 - 3370
First Differentiate and Then Operate (Or Not) Xavier M. Keutgen Endocrine Tumors 01 March 2022 Pages: 3371 - 3372
Editorial Comment to “High Expression of Bloom Syndrome Helicase is a Key Factor for Poor Prognosis and Advanced Malignancy in Patients with Pancreatic Cancer: A Retrospective Study” Yoshihide NannoHirochika Toyama Pancreatic Tumors 21 March 2022 Pages: 3373 - 3374
Weighing in on Ghrelin and the Preservation of Muscle After Esophagectomy Evan T. AlicubenAnthony W. Kim Thoracic Oncology 06 March 2022 Pages: 3375 - 3376
Efficacy of Neoadjuvant Intratumoral Darleukin/Fibromun (L19IL2 + L19TNF) in Patients with Clinical Stage IIIB/C Melanoma (Neo-DREAM) Areeba SaifAlexander J. RossiJonathan S. Zager ASO Research Letter 28 February 2022 Pages: 3377 - 3378
Pembrolizumab Compared with Standard-of-Care Observation in Treating Patients with Completely Resected Stage I–III Merkel Cell Cancer (STAMP) Martha E. TekeAlexander J. RossiBrian Gastman ASO Research Letter 08 March 2022 Pages: 3379 - 3380
Payer-Negotiated Prices for Breast Cancer Treatment at NCI-Designated Cancer Treatment Centers Angelin Tresa MathewBhav JainFumiko Chino ASO Research Letter 29 January 2022 Pages: 3381 - 3383
A Framework for Reporting Cohort Derivation in Studies Using the National Cancer Database Sarah R. KaslowRyan P. MerkowCamilo Correa-Gallego ASO Research Letter 03 March 2022 Pages: 3384 - 3386
Liver Isolation Oxaliplatin (LIOX): Long Term Survival from a New Locoregional Technique for Chemorefractory Patients with Colorectal Liver Metastases Nyan Y. KhinMadhawa De SilvaRodney J. Lane ASO Research Letter Open access 11 February 2022 Pages: 3387 - 3389
Iterative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Adenocarcinoma of the Appendix Felipe Lopez-RamirezVadim GushchinArmando Sardi Peritoneal Surface Malignancy 08 February 2022 Pages: 3390 - 3401
ASO Author Reflections: If at First You Don’t Succeed, Try, Try Again: Iterative CRS/HIPEC for Recurrent Mucinous Appendix Cancer Felipe Lopez-RamirezMary Caitlin KingArmando Sardi ASO Author Reflections 11 January 2022 Pages: 3402 - 3403
ASO Visual Abstract: Iterative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Adenocarcinoma of the Appendix Felipe Lopez-RamirezVadim GushchinArmando Sardi ASO Visual Abstract 24 January 2022 Pages: 3404 - 3404
Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Marco TonelloDario BarattiAntonio Sommariva Peritoneal Surface Malignancy 16 November 2021 Pages: 3405 - 3417
ASO Author Reflections: Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Marco TonelloAntonio Sommariva ASO Author Reflections 06 November 2021 Pages: 3418 - 3419
ASO Visual Abstract: Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Marco TonelloDario BarattiAntonio Sommariva ASO Visual Abstract 31 March 2022 Pages: 3420 - 3421
Timing of Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Low-Grade Appendiceal Mucinous Neoplasms Cristian D. ValenzuelaChristopher W. MangieriPerry Shen Peritoneal Surface Malignancy 07 March 2022 Pages: 3422 - 3431
ASO Author Reflections: When is the Best Time to Perform Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for a Recurrent Low-Grade Appendiceal Mucinous Neoplasm? Cristian D. ValenzuelaKonstantinos I. VotanopoulosPerry Shen ASO Author Reflections 07 March 2022 Pages: 3432 - 3433
ASO Visual Abstract: Timing of Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Low-Grade Appendiceal Mucinous Neoplasms Cristian D. ValenzuelaChristopher W. MangieriPerry Shen ASO Visual Abstract 06 March 2022 Pages: 3434 - 3435
Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis: A 30-year Institutional Experience Cristian D. ValenzuelaEdward A. LevinePerry Shen Peritoneal Surface Malignancy 14 March 2022 Pages: 3436 - 3445
ASO Author Reflections: Thirty Years of Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at Wake Forest University Cristian D. ValenzuelaEdward A. LevinePerry Shen ASO Author Reflections 11 March 2022 Pages: 3446 - 3447
ASO Visual Abstract: Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis—A 30-year Institutional Experience Cristian D. ValenzuelaEdward A. LevinePerry Shen ASO Visual Abstract 07 March 2022 Pages: 3448 - 3449
Weight Tracking as a Novel Prognostic Marker After Pancreatectomy Jonathan J. HueLee M. OcuinSarah C. Markt Pancreatic Tumors 23 January 2022 Pages: 3450 - 3459
ASO Author Reflection: Post-pancreatectomy Weight Trends Predict Recurrence and Survival Jonathan J. HueJordan M. WinterSarah C. Markt ASO Author Reflections 25 January 2022 Pages: 3460 - 3461
ASO Visual Abstract: Weight Tracking as a Novel Prognostic Marker After Pancreatectomy Jonathan J. HueLee M. OcuinSarah C. Markt ASO Visual Abstract 14 February 2022 Pages: 3462 - 3462
Systemic Therapy for Resected Pancreatic Adenocarcinoma: How Much is Enough? Kevin M. TurnerAaron M. DelmanSameer H. Patel Pancreatic Tumors 09 February 2022 Pages: 3463 - 3472
ASO Author Reflections: An Underappreciated Metric: Systemic Chemotherapy Dose Density in Pancreatic Cancer Kevin M. TurnerSameer H. Patel ASO Author Reflections 06 February 2022 Pages: 3473 - 3474
ASO Visual Abstract: Systemic Therapy for Resected Pancreatic Adenocarcinoma—How Much Is Enough? Kevin M. TurnerAaron M. DelmanSameer H. Patel ASO Visual Abstract 16 March 2022 Pages: 3475 - 3476
Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective, Lymphadenectomy Protocol Giuseppe MalleoLaura MagginoRoberto Salvia Pancreatic Tumors Open access 21 February 2022 Pages: 3477 - 3488
ASO Author Reflection: Location of Nodal Metastases in Pancreatoduodenectomy for Cancer: Which Station Matters? Giuseppe MalleoLaura MagginoRoberto Salvia ASO Author Reflections 25 February 2022 Pages: 3489 - 3490
ASO Visual Abstract: Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective Lymphadenectomy Protocol Giuseppe MalleoLaura MagginoRoberto Salvia ASO Visual Abstract 02 March 2022 Pages: 3491 - 3491
Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC) M. RedegalliM. Schiavo LenaC. Doglioni Pancreatic Tumors Open access 01 March 2022 Pages: 3492 - 3502
ASO Author Reflections: Prognostic Index after Neoadjuvant Chemotherapy (PINC) in Pancreatic Ductal Adenocarcinoma as Novel Tumor Regression Grading System Miriam RedegalliMarco Schiavo Lena ASO Author Reflections 20 February 2022 Pages: 3503 - 3503
ASO Visual Abstract: Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma Miriam RedegalliMarco Schiavo LenaClaudio Doglioni ASO Visual Abstract 21 March 2022 Pages: 3504 - 3504
Laparoscopic Radical Antegrade Modular Pancreatosplenectomy with Anterocranial Splenic Artery-First Approach for Left-Sided Resectable Pancreatic Cancer (with Videos) Tomotaka KatoYosuke InoueYu Takahashi Pancreatic Tumors 14 February 2022 Pages: 3505 - 3514
Comment on “Sarcopenia as a Predictor of Survival in Patients with Pancreatic Adenocarcinoma After Pancreatectomy” Ayfer DurakUmut Safer Pancreatic Tumors 16 March 2022 Pages: 3515 - 3516
More is More? Total Pancreatectomy for Periampullary Cancer as an Alternative in Patients with High-Risk Pancreatic Anastomosis: A Propensity Score-Matched Analysis Anna BurelliGiampaolo PerriGiovanni Marchegiani Pancreatic Tumors 19 March 2022 Pages: 3517 - 3518
Reply to: Letter to the Editor: More is More? Total Pancreatectomy for Periampullary Cancer as an Alternative in Patients with High-Risk Pancreatic Anastomosis: A Propensity Score-Matched Analysis, by Marchegiani, Giovanni et al. Sebastian HempelFlorian OehmeMarius Distler Pancreatic Tumors Open access 25 February 2022 Pages: 3519 - 3520
Correction to: Surgical Outcomes and Comparative Analysis of Transduodenal Ampullectomy and Pancreaticoduodenectomy: A Single-Center Study Eun-Ki MinSeung Soo HongHo Kyoung Hwang Correction 15 February 2022 Pages: 3521 - 3521
Surgical Treatment of Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: An NCDB Analysis Sarah R. KaslowGerardo A. VitielloCamilo Correa-Gallego Endocrine Tumors 05 March 2022 Pages: 3522 - 3531
ASO Author Reflections: Reconsidering Resection for Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma Sarah R. KaslowCamilo Correa-Gallego ASO Author Reflections 26 February 2022 Pages: 3532 - 3533
ASO Visual Abstract: Surgical Treatment of Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma—An NCDB Analysis Sarah R. KaslowGerardo A. VitielloCamilo Correa-Gallego ASO Visual Abstract 05 March 2022 Pages: 3534 - 3535
Clinical Predictors of Pseudohypoxia-Type Pheochromocytomas J. J. BaechleP. Marincola SmithC. M. Kiernan Endocrine Tumors 01 March 2022 Pages: 3536 - 3546
ASO Author Reflections: Clinical Predictors of Pseudohypoxia Cluster Type Pheochromocytomas Jordan J. BaechlePaula Marincola SmithColleen M. Kiernan ASO Author Reflections 03 April 2022 Pages: 3547 - 3548
ASO Visual Abstract: Clinical Predictors of Pseudohypoxia-Type Pheochromocytoma Jordan J. BaechlePaula Marincola SmithColleen M. Kiernan ASO Visual Abstract 21 March 2022 Pages: 3549 - 3550
High Expression of Bloom Syndrome Helicase is a Key Factor for Poor Prognosis and Advanced Malignancy in Patients with Pancreatic Cancer: A Retrospective Study Chuan LanYo-ichi YamashitaHideo Baba Translational Research 13 April 2022 Pages: 3551 - 3564
ASO Visual Abstract: High Expression of Bloom Syndrome Helicase is a Key Factor for Poor Prognosis and Advanced Malignancy in Patients with Pancreatic Cancer: A Retrospective Study Chuan LanYo-ichi YamashitaHideo Baba ASO Visual Abstract 22 March 2022 Pages: 3565 - 3566
Hepatectomy with Perioperative Chemotherapy for Multiple Colorectal Liver Metastases is the Available Option for Prolonged Survival Kiyohiko OmichiYosuke InoueAkio Saiura Translational Research 03 February 2022 Pages: 3567 - 3576
ASO Visual Abstract: Hepatectomy with Perioperative Chemotherapy for Multiple Colorectal Liver Metastases is the Available Option for Prolonged Survival Kiyohiko OmichiYosuke InoueAkio Saiura ASO Visual Abstract 03 March 2022 Pages: 3577 - 3577